

**HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF**

The present application is a continuation-in-part of U.S. Application No. 09/479,783, filed January 7, 2000, which is a divisional of U.S. Application No. 08/870,608, filed June 6, 1997, Patent No. 6,107,094, which is a  
5 continuation in part of U.S. Application No. 08/659,440, filed June 6, 1996, Patent No. 5,898,031. All of the above are assigned to the assignee of the present invention and are incorporated by reference herein in their entirety.

10 **Field of the Invention**

The present invention relates to a human RNase III, the gene for which has now been cloned and characterized, and compositions and uses thereof. Antisense inhibitors of human RNase III are also described.

15

**Background of the Invention**

Ribonuclease III (RNase III) is an endoribonuclease that cleaves double stranded RNA. The enzyme is expressed in many organisms and is highly conserved. I. S. Mian,  
20 *Nucleic Acids Res.*, **1997**, 25, 3187-95. All RNase III species cloned to date contain an RNase III signature sequence and vary in size from 25 to 50 kDa. Multiple functions have been ascribed to RNase In both *E. coli* and *S. cerevisiae*, RNase III has been reported to be involved  
25 in the processing of pre-ribosomal RNA (pre-rRNA). Elela et al., *Cell*, **1996**, 85, 115-24. RNase III has also been

05900425.070601

reported to be involved in the processing of small molecular weight nuclear RNAs (snRNAs) and small molecular weight nucleolar RNAs (snoRNAs) in *S. cerevisiae*. Chanfreau et al., *Genes Dev.* **1996**, 11, 2741-51; Qu et al., 5 *Mol. Cell. Biol.* **1996**, 19, 1144-58. In *E. coli*, RNase III has also been reported to be involved in the degradation of some mRNA species. D. Court, in *Control of messenger RNA stability*, **1993**, Academic Press, Inc, pp. 71-116.

A human double strand RNase (dsRNase) activity has 10 been described. Wu et al., *J. Biol. Chem.*, **1998**, 273, 2532-2542; Crooke, U.S. Patent 5,898,031; U.S. patent 6,017,094. By the rational design and testing of chemically modified antisense oligonucleotides that contained oligoribonucleotide stretches of varying length, a dsRNase 15 activity was demonstrated in human T24 bladder carcinoma cells which produced 5'-phosphate and 3'-hydroxyl termini upon cleavage of the complementary cellular RNA target. This pattern of cleavage products is a feature of *E. coli* RNase III. The cleavage activity in human cells required 20 the formation of a dsRNA region in the oligonucleotide. This human dsRNase activity is believed to be useful as an alternative terminating mechanism to RNase H for antisense therapeutics. Because it relies on "RNA-like" oligonucleotides, which generally have higher potency than 25 the "DNA-like" oligonucleotides required for RNase H activity, it may prove an attractive alternative to RNase H-based antisense approaches.

RNA interference (RNAi) is a form of sequence-specific, post-transcriptional gene silencing in animals 30 and plants, elicited by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. Elbashir et al., *Nature*, **2001**, 411, 494-498. dsRNA triggers the specific degradation of homologous RNAs, only within the region of homology. The dsRNA is processed to 21- to 23-

0990435-070504  
"0990435-070504"

nucleotide fragments, sometimes called short interfering RNAs (siRNAs) which are believed to be the guide fragments for sequence-specific mRNA degradation. The processing of longer dsRNA to these short siRNA fragments is believed to  
5 be accomplished by RNA III. Elbashir et al., *ibid.*, Elbashir et al., *Genes and Devel.*, **2001**, 15, 188-200. Thus it is believed that the human RNase III of the present invention may be useful in further understanding and exploiting the RNAi mechanism, particularly in human cells.

10 Despite the substantial information about members of the RNase III family and the cloning of genes encoding proteins with RNase III activity from a number of lower organisms (*E.coli*, yeast and others), no human RNase III has previously been cloned. This has hampered efforts to  
15 understand the structure of the enzyme(s), its distribution and the functions it may serve. The present application describes the cloning and characterization of a cDNA that expresses a human RNase III. Cloning and sequencing of the cDNA encoding human RNase III allowed characterization of  
20 the this nucleic acid as well as of the location and function of the RNase III protein itself.

#### Summary of the Invention

The present invention provides a polynucleotide  
25 sequence (set forth herein as SEQ ID NO: 1) which has been identified as encoding human RNase III by the homology of the calculated expressed polypeptide (provided herein as SEQ ID NO: 2) with known amino acid sequences of yeast and worm RNase III as well as by functional analysis.

30 The present invention provides polynucleotides that encode human RNase III, the human RNase III polypeptide, vectors comprising nucleic acids encoding human RNase III, host cells containing such vectors, antibodies targeted to human RNase III, nucleic acid probes capable of hybridizing  
35 to a nucleic acid encoding a human RNase III polypeptide,

0900425 070601

and antisense inhibitors of RNase III expression. Methods of inhibiting RNase III expression or activity are also provided, as are pharmaceutical compositions which include a human RNase III polypeptide, an antisense inhibitor of  
5 RNase III expression, or a vector containing a nucleic acid encoding human RNase III.

Methods for identifying agents which modulate activity and/or levels of human RNase III are also provided. Methods of promoting inhibition of expression of  
10 a selected protein via antisense, methods of screening oligonucleotides to identify active antisense oligonucleotides against a particular target, methods of prognosticating efficacy of antisense therapy, methods of promoting RNA interference (RNAi) in a cell and methods of  
15 eliciting cleavage of a selected cellular RNA target are also provided. All of these methods exploit the RNA-cleaving activity of RNase III. In preferred embodiments the oligonucleotides used in these methods are RNA-like oligonucleotides. Also provided are methods of identifying  
20 agents which increase or decrease activity or levels of human RNase III.

The polynucleotides, antisense oligonucleotides, polypeptides and other compounds, compositions and methods of the present invention are useful for research,  
25 biological and clinical purposes. For example, the polynucleotides and antisense oligonucleotides are useful in defining the roles of RNase III and the interaction of human RNase III and cellular RNA (including pre-mRNA or pre-rRNA).

30

#### **Brief Description of the Drawings**

Figure 1 shows the amino acid sequence of human RNase III (SEQ ID NO: 2) and a comparison of the sequence of the RNase III domain of the human RNase III to RNase III  
35 domains of *C. elegans* (Worm; SEQ ID NO: 3), *S. pombe* (PAC;

SEQ ID NO: 4) and *S. cerevisiae* (RNT; SEQ ID NO: 5) and *E. coli* (RNC; SEQ ID NO: 6). Bold letters: identical amino acids of human RNase III to other species. **@@@**: putative catalytic center. **HHH**: alpha helix; **BBB**: beta sheet (dsRNA binding region at C-terminus). Amino acid identity of human RNase III to Worm (41%), PAC (17%), RNT (15%) and RNC (16%). \*: Potential phosphorylation sites analyzed using OMIGA (Oxford Molecular Ltd.).

## 10 Detailed Description of the Invention

A cDNA encoding human RNase III has now been cloned and characterized. The cloned sequence is provided herein as SEQ ID NO: 1. This cDNA encodes a protein of 160 kDa which is ubiquitously expressed in human cell and tissue types, and is involved in processing of preribosomal RNA (pre-rRNA).

Thus, in accordance with one aspect of the present invention, there are provided isolated polynucleotides which encode human RNase III polypeptides. By "polynucleotides" it is meant to include any form of RNA or DNA such as mRNA, pre-mRNA or cDNA or genomic DNA, respectively, obtained by cloning or produced synthetically by well known chemical techniques. DNA may be double- or single-stranded. Single-stranded DNA may comprise the coding or sense strand or the non-coding or antisense strand.

Methods of isolating a polynucleotide of the present invention via cloning techniques are well known. For example, to obtain the polynucleotide sequence of SEQ ID NO: 1, a similarity search of the yeast RNT1 gene (RNase III, Genbank accession no. AAB04172; SEQ ID NO: 5) and the *Caenorhabditis elegans* RNase III gene (Genbank accession no. 001326; SEQ ID NO: 3) with the XREF database (National Center for Biotechnology Information, NIH, Rockville MD)

was performed. A 393 base pair (bp) human EST clone (GenBank AA083888) was identified.

Using primers based on this EST sequence, a clone (U4) corresponding to the COOH-terminal portion of the protein (nucleotides 3569-4764 of full length cDNA) was cloned by 3' RACE. Eight positive clones were isolated by screening a liver cDNA library with this clone. With primers based on one of these clones, 5' RACE was performed to clone a cDNA of approximately 1 kb, which corresponds to the middle part of the full length cDNA. In the same way, a cDNA of the NH<sub>2</sub>-terminal portion was cloned. Primers based on the NH<sub>2</sub>-terminal-most clone were used to perform additional 5'-RACE to obtain the NH<sub>2</sub>-terminal portion of the cDNA. The overlapping clones were sequenced and assembled to a full length human RNase II cDNA with a total of 4764 nucleotides. This human RNase III polynucleotide sequence is provided herein as SEQ ID NO: 1 and has been deposited as GenBank accession no. AF189011. The cDNA contained a coding sequence of 4125 nucleotides (from 246-4370 of SEQ ID NO:1) that was calculated to encode a 1374 amino acid protein. This polypeptide sequence is provided herein as SEQ ID NO: 2, shown in Figure 1. The calculated molecular weight of the protein is 160 kDa based on the prediction of the first translated methionine as the translation initiation site. Northern hybridization analyses demonstrated that the human RNase III mRNA was approximately 5 kb in size. It was found to be ubiquitously expressed in human tissues and cell lines. Compared to *C. elegans*, yeast and bacterial RNase III, human RNase III is substantially larger and contains multiple domains. The RNase III domain (amino acids 949-1374) is located at the carboxy terminus of the protein and is homologous to *C. elegans*, yeast and bacterial RNase III. The human RNase also contains proline rich (amino acids 1-220) and serine-arginine rich (amino acids 221-470) domains near the amino

terminus. The SR and RNase III domains are separated by 478 amino acids.

The RNase III domain of human RNase III is conserved with other species and is most homologous with *C. elegans* RNase III (41% identity). Both the human RNase III domain and *C. elegans* RNase III contain two RNase III signature sequences (HNERLEFLGDS; SEQ ID NO 7). Sequence identity was also compared with the yeasts *S. pombe* (PAC gene) (17% homology) and *S. cerevisiae* (RNT gene) (15% homology) and with *E. coli* RNase III (RNC gene) (16% homology). Human RNase III also contains multiple phosphorylation sites. The SR domain is usually present in SR or SR related proteins that play crucial roles in mRNA splicing. The fusion of SR and RNase III domains into a single protein suggests that human RNase III may be involved in a number of RNA metabolic events. The presence of multiple potential phosphorylation sites suggests that the enzyme is regulated by phosphorylation.

In a preferred embodiment, the polynucleotide of the present invention comprises the nucleic acid sequence of SEQ ID NO: 1. However, as will be obvious to those of skill in the art upon this disclosure, due to the degeneracy of the genetic code, polynucleotides of the present invention may comprise other nucleic acid sequences encoding the polypeptide of SEQ ID NO: 2 and derivatives, variants or active fragments thereof.

Another aspect of the present invention relates to the polypeptides encoded by the polynucleotides of the present invention. In a preferred embodiment, a polypeptide of the present invention comprises the deduced amino acid sequence of human RNase III provided in SEQ ID NO: 2. However, by "polypeptide" it is also meant to include fragments, derivatives and analogs of SEQ ID NO: 2 which retain essentially the same biological activity and/or function as human RNase III. Alternatively,

polypeptides of the present invention may retain their ability to bind to double stranded RNA even though they do not function as active RNase III enzymes in other capacities. In another embodiment, polypeptides of the present invention may retain nuclease activity but without specificity for an RNA/RNA duplex. Polypeptides of the present invention include recombinant polypeptides, isolated natural polypeptides and synthetic polypeptides, and fragments thereof which retain one or more of the activities described above.

To confirm the expression of the human RNase III protein, two anti-peptide antibodies were produced. The "anti-III" peptide antibody was derived from a peptide corresponding to amino acids 1356-1374 within the RNase III domain present in the C-terminal portion of the putative protein. The "anti-SR" peptide antibody was derived from a peptide corresponding to amino acids 266-284 within the SR-domain of the putative protein. Using these antibodies, Western blot analyses were performed to determine the size and localization of human RNase III. The anti-SR peptide antibody recognized a band in HeLa whole cell lysate with a molecular weight of approximately 160 kDa which is near the calculated protein size confirming that the full coding region is expressed in HeLa cells. Similar experiments were performed using different human cell lines e.g. A549, T24 and HL60 with equivalent results. To determine the localization of the protein, nuclear and non-nuclear fractions from HeLa cells and other human cell lines were prepared and equal amounts of proteins were analyzed by Western blots. RNase III was present primarily in the nuclear fractions. Non-nuclear fractions contained only trace amounts of protein, possibly due to the contamination during sample preparation. The anti-III peptide antibody gave results equivalent to those obtained with the anti-SR peptide antibody. To better understand the localization of



human RNase III, the protein was identified in cells by indirect immunofluorescence microscopy. The nuclei of HeLa cells were stained by both anti-SR and anti-III antibodies, confirming that human RNase III is present in the nucleus.

- 5 RNase III is localized extensively in nucleus and occasionally observed in nucleoli. This localization suggests possible involvement in both pre-mRNA and pre-rRNA processing. In *E.coli*, RNase III is associated with ribosomes in the cytoplasm. Robertson et al., *J. Biol. Chem*, **1968**, 243, 82-91. Eukaryotic RNase III has not previously been shown to be localized in the nucleus.

10 The localization of human RNase III to nucleoli was found to be cell cycle regulated. Double thymidine treatment was used to synchronize HeLa cells to early-S phase. Two to four hours after releasing the thymidine block, HeLa cells entered S phase as determined by fluorescence activated cell sorting (FACS). Six to eight hours after release, HeLa cells entered the G2/M phase. There were no significant changes in the mRNA or protein levels of the RNase III during pre-S, S or G2/M phases. However, the subcellular localization of the protein changed during the cell cycle. When the cells were treated with thymidine and synchronized in early S phase, RNase III protein was present only in the nucleus and not the nucleoli, as determined by immunofluorescent labeling. After releasing from thymidine block, RNase III was translocated to nucleoli, reaching a peak at 4 hours when cells were in S phase. At that time, RNase III was present both in the nucleoli and the nucleus. The protein was present in the nucleoli for approximately 8 hours, and then disappeared from nucleoli as cells entered M phase. Localization of RNase III in the nucleoli was confirmed by double staining with an anti-nucleolin monoclonal antibody (MBL, Watertown, MA).

05900423-070601

In human cells, nucleoli undergo phases of condensation and dissociation as a function of the cell cycle. Nucleoli dissociate upon entering prophase and disappear entirely during the late prophase and metaphase periods of mitosis, then begin to reappear during telophase and form dense organelles during the G1 phase. Human RNase III was only translocated to and remained in the nucleoli during S phase suggesting that RNase III may serve one or more specific functions in nucleoli during S phase.

The present invention also provides antisense inhibitors of RNase III expression, which may be used, for example, therapeutically, prophylactically or as research reagents. The modulation of function of a target nucleic acid (in this case a nucleic acid encoding RNase III) by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of the target. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose

09900425.070601

function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in vivo*. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used *in vivo* to initiate translation of the target, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one

of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions,

known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds.

"Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable"

09900435 070601

and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of *in vivo* assays or therapeutic treatment, and in the case of *in vitro* assays, under conditions in which the assays are performed.

Antisense and other compounds of the invention which hybridize to the target and inhibit expression of the target are identified through experimentation, and the sequences of these compounds are hereinbelow identified as preferred embodiments of the invention. The target sites to which these preferred sequences are complementary are hereinbelow referred to as "active sites" and are therefore preferred sites for targeting. Therefore another embodiment of the invention encompasses compounds which hybridize to these active sites.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a

biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic  
5 uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are  
10 presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term  
15 "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as  
20 oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic  
25 acid target and increased stability in the presence of nucleases.

In general, nucleic acids (including oligonucleotides) may be described as "DNA-like" (i.e., having 2'-deoxy sugars and, generally, T rather than U  
30 bases) or "RNA-like" (i.e., having 2'-hydroxyl or 2'-modified sugars and, generally U rather than T bases). Nucleic acid helices can adopt more than one type of structure, most commonly the A- and B-forms. It is believed that, in general, oligonucleotides which have B-form-like

09900425-070501

structure are "DNA-like" and those which have A-form-like structure are "RNA-like".

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends  
5 other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 50  
10 nucleobases (i.e. from about 8 to about 50 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic  
15 RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes  
20 of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be  
25 linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric structure can be further joined to  
30 form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and  
35 DNA is a 3' to 5' phosphodiester linkage.

090403070604



Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131;

5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677;  
5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111;  
5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555;  
5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of  
5 which are commonly owned with this application, and each of  
which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do  
not include a phosphorus atom therein have backbones that  
are formed by short chain alkyl or cycloalkyl  
10 internucleoside linkages, mixed heteroatom and alkyl or  
cycloalkyl internucleoside linkages, or one or more short  
chain heteroatomic or heterocyclic internucleoside  
linkages. These include those having morpholino linkages  
(formed in part from the sugar portion of a nucleoside);  
15 siloxane backbones; sulfide, sulfoxide and sulfone  
backbones; formacetyl and thioformacetyl backbones;  
methylene formacetyl and thioformacetyl backbones;  
riboacetyl backbones; alkene containing backbones;  
sulfamate backbones; methyleneimino and methylenehydrazino  
20 backbones; sulfonate and sulfonamide backbones; amide  
backbones; and others having mixed N, O, S and CH<sub>2</sub> component  
parts.

Representative United States patents that teach the  
preparation of the above oligonucleosides include, but are  
25 not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444;  
5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564;  
5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677;  
5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289;  
5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070;  
30 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and  
5,677,439, certain of which are commonly owned with this  
application, and each of which is herein incorporated by  
reference.

In other preferred oligonucleotide mimetics, both the  
35 sugar and the internucleoside linkage, i.e., the backbone,

0990425-070601

of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, **1991**, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular  $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$ ,  $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$  [known as a methylene (methylimino) or MMI backbone],  $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$ ,  $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$  and  $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$  [wherein the native phosphodiester backbone is represented as  $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$ ] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted  $\text{C}_1$

to C<sub>10</sub> alkyl or C<sub>2</sub> to C<sub>10</sub> alkenyl and alkynyl. Particularly preferred are O[(CH<sub>2</sub>)<sub>n</sub>O]<sub>m</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>OCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>ONH<sub>2</sub>, and O(CH<sub>2</sub>)<sub>n</sub>ON[(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>]<sub>2</sub>, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C<sub>1</sub> to C<sub>10</sub> lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH<sub>3</sub>, OCN, Cl, Br, CN, CF<sub>3</sub>, OCF<sub>3</sub>, SOCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, **1995**, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminoethoxy, i.e., a O(CH<sub>2</sub>)<sub>2</sub>ON(CH<sub>3</sub>)<sub>2</sub> group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>2</sub>)<sub>2</sub>, also described in examples hereinbelow.

A further preferred modification includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene (-CH<sub>2</sub>-)<sub>n</sub> group bridging the 2' oxygen atom and the 3' or 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

Other preferred modifications include 2'-methoxy (2'-O-CH<sub>3</sub>), 2'-aminopropoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>), 2'-allyl (2'-CH<sub>2</sub>-CH=CH<sub>2</sub>), 2'-O-allyl (2'-O-CH<sub>2</sub>-CH=CH<sub>2</sub>) and 2'-fluoro (2'-F).

The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl ( $-C\equiv C-CH_3$ ) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-

trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, **1990**, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, **1991**, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, **1993**. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyl-adenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, **1993**, pp. 276-278) and

09900425 070601

are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the  
5 preparation of certain of the above noted modified  
nucleobases as well as other modified nucleobases include,  
but are not limited to, the above noted U.S. 3,687,808, as  
well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273;  
5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908;  
10 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121,  
5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588;  
6,005,096; and 5,681,941, certain of which are commonly  
owned with the instant application, and each of which is  
herein incorporated by reference, and United States patent  
15 5,750,692, which is commonly owned with the instant  
application and also herein incorporated by reference.

Another modification of the oligonucleotides of the  
invention involves chemically linking to the  
oligonucleotide one or more moieties or conjugates which  
20 enhance the activity, cellular distribution or cellular  
uptake of the oligonucleotide. The compounds of the  
invention can include conjugate groups covalently bound to  
functional groups such as primary or secondary hydroxyl  
groups. Conjugate groups of the invention include inter-  
25 calators, reporter molecules, polyamines, polyamides, poly-  
ethylene glycols, polyethers, groups that enhance the  
pharmacodynamic properties of oligomers, and groups that  
enhance the pharmacokinetic properties of oligomers.  
Typical conjugates groups include cholesterol, lipids,  
30 phospholipids, biotin, phenazine, folate, phenanthridine,  
anthraquinone, acridine, fluoresceins, rhodamines,  
coumarins, and dyes. Groups that enhance the pharmaco-  
dynamic properties, in the context of this invention,  
include groups that improve oligomer uptake, enhance  
35 oligomer resistance to degradation, and/or strengthen

09300435 070601  
T09020 5240656

sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion.

- 5 Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed October 23, 1992 the entire disclosure of which is incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, **1989**, 10 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1994**, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, **1992**, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1993**, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, **1992**, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, **1991**, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, 259, 327-330; Svinarchuk et al., 20 *Biochimie*, **1993**, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, 18, 3777-3783), a polyamine or a 25 polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, **1995**, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, 1264, 229-237), or an octadecylamine or hexylamino- 30 carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, **1996**, 277, 923-937).

Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen,

03900425-070601



(S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.

Oligonucleotide-drug conjugates and their preparation are described in United States Patent Application 09/334,130 (filed June 15, 1999) which is incorporated herein by reference in its entirety.

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention preferably includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more

chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids.

By way of example, RNase H cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Oligonucleotides, particularly chimeric oligonucleotides, designed to elicit target cleavage by RNase H, thus are generally more potent than oligonucleotides of the same base sequence which are not so optimized. Cleavage of the RNA target can be routinely detected by, for example, gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric oligonucleotides may have one or more modifications of the internucleoside (backbone) linkage, the sugar or the base. In a preferred embodiment, the oligonucleotide is a chimeric oligonucleotide having a modification at the 2' position of at least one sugar moiety. Presently believed to be particularly preferred are chimeric oligonucleotides which have approximately four or more deoxynucleotides in a row, which provide an RNase H

05900425.070604

cleavage site, flanked on one or both sides by a region of 2'- modified oligonucleotides.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more  
5 oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid  
10 structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is  
15 herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors  
20 including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

25 Antisense inhibition of human RNase III expression was used to further evaluate the role(s) of RNase III. To identify optimal sites in RNase III mRNA for antisense effects, 2'-O-methoxyethyl chimeric antisense oligonucleotides targeted to 10 sites in the mRNA were  
30 designed and screened for inhibition of RNase III. These are shown in Table 1. These chimeric or "gapped" oligonucleotides are designed to serve as substrates for RNase H when bound to RNA resulting in degradation of the target RNA and oligonucleotides of this type have been

09500425 070601  
T09020 52400660

shown to be highly specific when used under the dexcribed conditions.

0900425 070604

ISPH-0522

- 29 -

PATENT

Table 1  
Antisense inhibition of human RNase III

ISIS #	Sequence (5'--> 3')	Target sites	% Inhibition	SEQ ID NO:
25690	<b>ATCCCTTTCTTCCGCATGTG</b>	3051-3070	79	8
25691	<b>GCCAAAGCGTGACATGATAT</b>	3085-4004	96	9
25692	<b>CGGATCATTTAAAGAGCAAGC</b>	3442-3461	78	10
25693	<b>TATTCACCAAGAGCTTCGC</b>	3776-3795	49	11
25694	<b>CAATCGTGGAAAGAACAGA</b>	3973-3992	50	12
25695	<b>GCTCCCATTTCCGCTTGCTG</b>	4197-4216	81	13
25696	<b>ATGCTCTCTTTCCACCTCA</b>	4308-4327	70	14
25697	<b>AAATACTCCACACTTGCATG</b>	4378-4397	79	15
25698	<b>TGCACATTCAACCAAGTCAA</b>	4420-4439	44	16
25699	<b>AGCTTAGGGTCACAACTCTGG</b>	4688-4707	31	17
27110	<b>TTCAGTTGTAGTGCTCCGAC</b>	3-mismatch of 25691	N/D	18

All oligonucleotides in Table 1 have phosphorothioate (P=S or PS) backbones and 2'-methoxyethoxy (2'MOE) "wings" flanking a 2'deoxy gap. 2'MOE nucleotides are shown in **bold**. All cytosines are 5-methyl cytosines (5meC). Target site refers to nucleotide numbers on the cloned RNase III cDNA (SEQ ID NO: 1) to which the oligonucleotide binds. Oligonucleotide concentration was 200 nM.

Table 1 shows that ISIS 25690, 25691, 25692, 25693, 25694, 25695, 25696 and 25697 (SEQ ID NO: 8, 9, 10, 11, 12, 13, 14 and 15) inhibited human RNase III expression by about 50% or more. These compounds are therefore preferred. The most effective agent was ISIS 25691 (SEQ ID NO: 9), targeted to nucleotides 3085-4004 in the coding region of the mRNA. This compound was selected for further studies.

Increasing concentrations of ISIS 25691 caused increasing loss of RNase III mRNA, with 300nM resulting in loss of more than 90% of the RNase III mRNA. The mismatch control oligonucleotide, ISIS 27110 (SEQ ID NO: 18), at 300nM had no effect on the RNase III mRNA level. ISIS 25691 at 300nM suppressed RNase III mRNA levels in HeLa cells from 2 to 72 hours after a single treatment. After treatment with ISIS 25691 at 100, 150 or 200nM for 24 hours, RNase III protein was reduced to 67%, 44% or 19% of control respectively. The level of RNase III protein was slightly reduced at 5 hours after treatment and reached a maximum reduction of about 70% at 18 hours. Immunofluorescence staining showed that after treatment with ISIS 25691 (150nM, 24 hours), RNase III was dramatically reduced or absent in the nucleus and nucleoli. After treatment of HeLa cells with ISIS 25691 at 300nM for 18 hours, the morphology of HeLa cells changed from fusiform to oval. After 24 hours of treatment, approximately 5-10% of the cells detached from the plate and could be stained with trypan blue indicating cell death. The cells that remained attached to the solid substrate grew much more slowly than untreated cells and appeared unable to enter mitosis (data not shown). After 48 hours, 40-50% of the cells treated with 300nM ISIS 25691 were dead. These results were highly reproducible and indicate that RNase III is required for HeLa cell survival. The

control oligonucleotide had no effect at any time or at any concentration on cell morphology, RNase III mRNA or protein levels demonstrating the antisense effect was highly specific.

5 One function that has been attributed to RNase III in lower species is pre-ribosomal RNA (pre-rRNA) processing. Human pre-rRNA processing is thought to involve cleavage of 45S pre-rRNA into 30S and 32S fragments. The 32S RNA product of the cleavage of 45S pre-rRNA contains 5.8S rRNA, ITS2 and 28S rRNA. 10 Cleavage of the 32S RNA results in 12S pre-rRNA and 28S rRNA products. The 12S pre-rRNA is further cleaved to 5.8S rRNA. Because ribosomes are made in the nucleolus, and the human RNase III protein appeared to be 15 translocated to and from the nucleolus during the cell cycle, its potential role(s) in human pre-rRNA processing was evaluated. Two hybridization probes for human pre-rRNA were synthesized, 5'ETS-1 (5'-CAA GGC ACG CCT CTC AGA TCG CTA GAG AAG GCT TTT CTC A-3'; SEQ ID NO: 19), designed to bind to the 5' external transcribed spacer (5'ETS) of human pre-rRNA and 5.8S-1 (5'-CAT TAA TTC TCG CAG CTA GCG CTG CGT TCT TCA TCG ACG C-3'; SEQ ID NO: 20), designed to bind to 5.8S rRNA. 20 When total cellular RNA (15µg) from untreated HeLa cells was fractionated by agarose gel electrophoresis, transferred to a nylon membrane and probed with <sup>32</sup>P-5'ETS-1, a band corresponding to 45S pre-rRNA and a very faint band corresponding in mobility to 30S (5'ETS-18S-ITS1) pre-rRNA were observed. When <sup>32</sup>P-5.8S-1 was used, bands corresponding to 45S, 32S (5.8S-ITS2-28S) and 12S (5.8S-ITS2) pre-rRNA and 5.8S rRNA were 30 observed. At concentrations at which the antisense oligonucleotide ISIS 25691 dramatically reduced the RNase III level, no effect on the 45S pre-rRNA level was observed. In contrast, the 5.8S-1 probe 35

00900435 "070601  
T0930D" 5240666

demonstrated that antisense inhibition of RNase III increased the levels of 32S and 12S pre-rRNAs.

To provide further confirmation that human RNase III is involved in preribosomal RNA processing, the effects of ten antisense oligonucleotides on RNase III mRNA levels were compared to the effects of these oligonucleotides on accumulation of the two pre-rRNA species (32S and 12S) that accumulated after treatment with the most potent of the antisense inhibitors, ISIS 25691. The potency of antisense inhibitors designed to bind to different sites in RNase III mRNA varied. The correlation between the reduction of RNase III RNA levels and the accumulation of both 32S and 12S pre-rRNAs was excellent, thus confirming the conclusion derived from the Northern blot analysis.

Antisense inhibition of RNase III resulted in substantial accumulation of 12S pre-rRNA, less pronounced accumulation of 32S pre-rRNA and no accumulation of 45S pre-rRNA. Thus this human RNase III appears to be required for the processing of 12S pre-rRNA. It may also be involved in the processing of 32S pre-rRNA. The principal site of cleavage induced by human RNase III described here is in the 5.8S-ITS2 region of pre-rRNA.

RNase III enzymes are double-strand RNA (dsRNA) endoribonucleases. To test whether the human RNase III domain can specifically cleave dsRNA, the RNase III domain-coding region was subcloned into a glutathione S-transferase (GST) expression vector. The GST-RNase III fusion protein and GST alone were expressed, purified using glutathione agarose and analyzed by coomassie blue staining of the SDS-PAGE and Western Blot analysis with anti-human RNase III peptide antibody. These studies showed that the human RNase III domain was greater than 85% pure, though there was

09900459 070601



evidence of slight degradation during expression and purification. When incubated with labeled dsRNA and ssRNA, the GST-RNase III fusion protein preferentially digested the dsRNA without significant cleavage of ssRNA, while GST alone cleaved neither dsRNA nor ssDNA substrate. Thus, the cleavage observed was not due to contamination with ssRNases or dsRNases from *E. coli*. Ribonucleases V<sub>1</sub> (dsRNase), and T<sub>1</sub> and A (ssRNases) were used as controls to confirm that the cleavage observed was dsRNA cleavage.

RNase III is a double-strand RNA endonuclease, specifically cleaving double-helical structures in cellular and viral RNAs. It is believed that this cleavage can be exploited to promote cleavage of a cellular RNA target, by providing "RNA-like" antisense oligonucleotides which hybridize to the cellular RNA target to form an RNA duplex, thus eliciting RNase III cleavage. Methods of promoting inhibition of expression by antisense oligonucleotides, and methods for screening oligonucleotides are thus provided. In the context of this invention, "promoting antisense inhibition" or "promoting inhibition of expression" of a selected RNA target, or of its protein product, means inhibiting expression of the target or enhancing the inhibition of expression of the target. In some embodiments of these methods, the RNase III is present in an enriched amount. In the context of this invention, "enriched" means an amount greater than would naturally be found. RNase III may be present in an enriched amount through, for example, addition of exogenous RNase III, through selection of cells which overexpress RNase III or through manipulation of cells to cause overexpression of RNase III. The exogenously added RNase III may be added in the form of, for example, a cellular or tissue extract, a biochemically

purified or partially purified preparation of RNase III, or a cloned and expressed RNase III polypeptide.

5 The expression of large quantities of a cloned human RNase III of the present invention has been shown to be useful in characterizing the activities of this enzyme. In addition, the polynucleotides and polypeptides of the present invention provide a means for identifying agents, such as the antisense compounds described herein, which modulate the function of this

10 enzyme in human cells and tissues. For example, a host cell can be genetically engineered to incorporate polynucleotides and express polypeptides of the present invention. Polynucleotides can be introduced into a host cell using any number of well known techniques

15 such as infection, transduction, transfection or transformation. The polynucleotide can be introduced alone or in conjunction with a second polynucleotide encoding a selectable marker. In a preferred embodiment, the host comprises a mammalian cell. Such

20 host cells can then be used not only for production of human RNase III, but also to identify agents which increase or decrease levels of expression or activity of human RNase III in the cell. In these assays, the host cell would be exposed to an agent suspected of

25 altering levels of expression or activity of human RNase III in the cells. The level or activity of human RNase III in the cell would then be determined in the presence and absence of the agent. Assays to determine levels of protein in a cell are well known to those of

30 skill in the art and include, but are not limited to, radioimmunoassays, competitive binding assays, Western blot analysis and enzyme linked immunosorbent assays (ELISAs). Methods of determining increased activity of the enzyme, and in particular increased cleavage of

35 dsRNA substrate can be performed in accordance with the

teachings of the examples of the present application. Agents identified as modulators of the level or activity of this enzyme may be useful.

Antisense modulators of human RNase III are  
5 provided herein and may be used diagnostically, therapeutically and for research purposes.

The following nonlimiting examples are provided to further illustrate the present invention.

## 10 **EXAMPLES**

### **Example 1**

#### **cDNA cloning**

An internet search of the XREF database in the National Center of Biotechnology Information (NCBI)  
15 yielded a 393 base pair (bp) human expressed sequenced tag (EST, GenBank accession AA083888), homologous to the yeast RNase III (RNT1) gene (GenBank accession #AAB04172; SEQ ID NO: 5) and the *C.elegans* RNase III gene (GenBank accession 001326; SEQ ID NO: 3). Three  
20 sets of oligonucleotide primers encoding the human RNase H EST sequence were synthesized. Sequence-specific primer sets listed in Table 2 were designed based on the human expressed tag sequence or early cloned cDNA fragments. These are shown in Table 2.  
25 These primers were used in polymerase chain reaction for 3' and 5' RACE and/or for detection on Southern blots.

Table 2  
RNase III Oligonucleotide Primers

Primer name	Sequence source	Position in full length cDNA	Primer Sequence	SEQ ID NO
NIII-2	EST AA083888	3516-3550	CCAAATACTGATCGACAACCTATTGAAACTTCTCC	21
NIII-4	EST AA083888	3569-3606	GAGTTGAAGAAGCAATTGGAGTAATTTTACTCATG	22
NIII-6	EST AA083888	3607-3634	TCGACTTCTGGCAAGGGCATTACACATT	23
3RACE3	Clone #3-4	2708-2683	CCTCTGTGCCAGCTTCTGTTTGTGTCAG	24
3RACE2	Clone #3-4	2688-2663	TGTCAGTTTGTGTTTGTGACTTTGGGACTA	25
3RACE1	Clone #3-4	2662-2637	TTTGCTAGGAGGTGGCGAAGTTTCAC	26
RACE4	Clone #L40	1923-1894	GCTTGATGGCCTCTTCTCCAGGATAAATGC	27
RACE5	Clone #L40	1898-1869	AATGCTGTGCCTAATTCCCTGTGCGTCTTGC	28
RACE Det	Clone #L40	1723-1676	CAGGTGCTGTCCCTCATCAGACTCACACTCGGATTCAGTGGAACTCTCT	29
33G	Clone #25	831-806	CACTGGCAGGAAAGAACTAGGGTTG	30
33H	Clone #25	802-776	TGGAACTATTAAAACTGGGAGGTGG	31
33 Det	Clone #25	701-652	AGGCATGGAGGGAGGGGCGATCATGAAGGGGAAAGTGCCTTGTCAGGAG	32

5

10

15

By 3' RACE (rapid amplification of 3' cDNA), the human RNase III cDNA 3' from the expressed tag sequence was amplified by PCR using human Marathon ready cDNA (Clontech, Palo Alto CA) as templates, and NIII-2/AP1 (for the first amplification) and NIII-4/AP2 (for the second amplification) as primers. AP1 and AP2 are primers provided with the Marathon ready cDNA by the manufacturer. The standard DNA polymerase chain reaction (PCR) procedure was performed using native pfu DNA polymerase (Stratagene, San Diego CA) and its reaction buffer. The annealing temperature was 55-60°C. The elongation time was approximately 6-8 min. The fragments were subjected to agarose gel electrophoresis. The fragments were subjected to agarose gel electrophoresis in the TAE buffer, denatured in 0.5 M NaOH and then electronically transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA) for confirmation by Southern blot. Southern blots were performed using [<sup>32</sup>P]-end labeled NIII-6 oligonucleotide as a probe in hybridization buffer (6x SSC, 5x Denhardt's solution) containing 100 µg/ml sheared denatured salmon sperm DNA, 0.5% SDS, 10 mM EDTA at 46°C for 4 hr, then washed twice with 1x SSC and 0.1% SDS at 42-59°C for 20 min. The confirmed fragments were excised from the agarose gel and purified by gel extraction (Qiagen, Germany), then subcloned into a zero-blunt vector (Invitrogen, Carlsbad, CA) and subjected to DNA sequencing.

**Example 2****Screening of the cDNA libraries, DNA sequencing and sequence analysis**

5 A human liver cDNA lambda phage Uni-ZAP library (Stratagene, La Jolla, CA) was screened using the RACE products as specific probes. Several positive clones were isolated. The two longest clones, 3-1 and 3-4, correspond to the COOH-terminal region, nucleotides 2636-3912 and 3350-4764, respectively, of the full  
10 length cDNA. With primers (3RACE1, 3RACE2 and 3RACE3) based on the NH<sub>2</sub>-terminal portion of the clone 3-4, 5' RACE was performed to clone a cDNA (clone L40) of approximately 1 kb, which encodes the middle part (nucleotides 1661-2688) of the full length cDNA. In the  
15 same way, a cDNA (clone 25) of the NH<sub>2</sub>-terminal portion (nucleotides 645-1898) was cloned. Using clone 25 to screen the liver library again, several clones were isolated, but none included additional NH<sub>2</sub>-terminal sequence. The most NH<sub>2</sub>-terminal clone (328)  
20 corresponded to nucleotides 799-2191. The last 5' RACE was performed with primers 33G, 33H and 33Dec, based on clone 25, and the NH<sub>2</sub>-terminal portion of the cDNA (clone 81, corresponding to nucleotides 1-802) was generated.

25 The positive cDNA clones were excised into pBluescript phagemid from lambda phage and subjected to DNA sequencing. Sequencing of the positive clones was performed with an automatic DNA sequencer by Retrogen Inc. (San Diego, CA). The overlapping sequences were  
30 aligned and combined by the assembling program of MacDNASISv3.0 (Hitachi Software Engineering Co., America, Ltd.) to give the full length (4764

09900425 "070601

nucleotides) polynucleotide sequence (SEQ ID NO: 1). Protein structure and analysis were performed by the program MacVector v6.0 (Oxford Molecular Group, UK). A homology search was performed on the NCBI database.

### 5 **Example 3**

#### **Antisense treatment**

HeLa cells were transfected with oligonucleotide mixed with Lipofectin (GIBCO BRL, Gaithersburg, MD) at a concentration of 37.5-300 nM for 5 hours in Opti-MEM  
10 (GIBCO BRL). After removing the medium containing oligonucleotide, cells were cultured in DMEM for times indicated and harvested for analysis. Inhibition by antisense oligonucleotides is expressed compared to control (without oligonucleotide treatment).

### 15 **Example 4**

#### **Northern hybridization**

Total RNA was isolated from HeLa cells using the guanidine isothiocyanate method (R. E. Kingston, in *Current protocols in molecular biology*, F. M. Ausubel, et al., Eds., John Wiley & Sons Inc., New York, 1997, vol. 1, pp. 4.2.3-4.2.5.). Fifteen µg of total RNA was separated on a 1 % agarose/formaldehyde gel and transferred to Hybond-N+ (Amersham, Arlington Heights, IL) followed by fixing using UV crosslinker  
20 (Stratagene, La Jolla, CA). To detect RNase III mRNA, hybridization was performed by using <sup>32</sup>P-labeled human RNase III cDNA in Quik-Hyb buffer (Stratagene, La Jolla, CA) at 68°C for 2 hours. After hybridization, membranes were washed in a final stringency of 0.1X  
30 SSC/0.1% SDS at 60°C for 30 minutes. Membranes were

analyzed using a PhosphorImager Storm 860 (Molecular Dynamics, Sunnyvale, CA). The level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used to normalize the amount of total RNA loaded.

5 For Northern hybridization of pre-rRNAs, HeLa cells were treated with ISIS 25691 and ISIS 27110 for 24 hours using <sup>32</sup>P-end labeled oligo probes 5'ETS-1 (5'- CAA GGC ACG CCT CTC AGA TCG CTA GAG AAG GCT TTT CTC A-3'; SEQ ID NO: 33), corresponding to 5'ETS and  
10 5.8S-1 (5'-CAT TAA TTC TCG CAG CTA GCG CTG CGT TCT TCA TCG ACG C-3'; SEQ ID NO: 34), corresponding to 5.8S rRNA. Hybridizations were performed at 40°C for 2 hours and washed in 2XSSC/0.1%SDS at 40°C for 1 hour. All others were as described above. Data were mean ±SD of  
15 triplicate determination of representative experiment.

#### Example 5

#### Western blot analysis of human RNase III

Nuclear and non-nuclear fractions from HeLa cells were prepared as described (Dignam et al., *Nucleic Acids Res* **1983**, 11, 1475-89. Whole cell, non-nuclear and nuclear fractions were boiled in SDS-sample buffer. Then the samples were separated by SDS-PAGE using 4 - 20% Tris-glycine gels (NOVEX, San Diego, CA) under reducing conditions. Molecular weight prestained  
25 markers were used (NOVEX) to determine the protein sizes. The proteins were electrophoretically transferred to a PVDF-membrane and processed for immunoblotting using affinity purified anti-SR peptide antibody at 5µg/ml. The immunoreactive bands were visualized using  
30 the enhanced chemiluminescence method (Amersham, Arlington Heights, IL) and analyzed using a

090045 070601



PhosphorImager Storm 860 (Molecular Dynamics,  
Sunnyvale, CA).

### Example 6

#### Antibody production

5           Antibodies were prepared to peptides synthesized  
having amino acid sequences contained within the SR  
domain and the III domain of human RNase III. The SR  
domain peptide (H-CRSDYDRGRTPSRHRSYERS-OH, amino acids  
226 to 284; SEQ ID NO: 35) and the III region peptide  
10 (H-CRWEREHQEREPDETEDIKK-OH, amino acids 1356 to 1374;  
SEQ ID NO: 36) were synthesized, coupled to diphtheria  
toxoid through maleimidocaproyl-N-hydroxysuccinamide  
(MCS), mixed with Freund's adjuvant (complete for first  
immunization, incomplete for remaining immunizations)  
15 and injected intramuscularly into New Zealand White  
rabbits. Serum was collected after the second  
immunization. Antibody titer was measured by ELISA.  
Anti-SR and anti-III peptide IgGs were affinity  
purified with SR and III peptides coupled to  
20 thiopropyl-Sepharose 6B, respectively.

### Example 7

#### Indirect immunofluorescence staining of human RNase III

HeLa cells were cultured in chamber slides for  
immunostaining. Cells were washed once with Dulbecco's  
25 Phosphate Buffered Saline (D-PBS, pH7.0), and then  
fixed in 10% neutral-buffered formalin for 10 minutes  
followed by washing three times with D-PBS. Fixed cells  
were then blocked for 30 minutes with 20% fetal bovine  
serum plus 0.5% Tween 20. Cells were first stained with  
30 anti-III peptide antibody (10µg/ml) for 1 hour at 37°C,

washed three times with D-PBS plus 0.1% NP-40, and incubated for 1 hour at 37°C with the FITC goat anti-rabbit IgG (Jackson ImmunoResearch Laboratory, Inc. West Grove, PA). The cells were washed with D-PBS three  
5 times and mounted in mounting medium (Vector, Burlingame, CA) for examination under a fluorescence microscope. NR IgG: normal rabbit IgG was used as control.

### Example 8

#### 10 Indirect immunofluorescence staining of human RNase III in HeLa cells in different phases of the cell cycle.

HeLa cells were synchronized at early-S phase using the double thymidine method (Johnson et al., in *The Cell Cycle: A Practical Approach* P. Fantes, R. Brooks, Eds., IRL Press, 1993, pp. 1-24). Briefly,  
15 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, 10% fetal calf serum) containing 2mM of thymidine for 17 hours. After washing twice with D-PBS, cells were cultured in DMEM for 9 hours followed by  
20 second thymidine treatment for 15 hours. Synchronized cells were then washed twice with D-PBS, cultured and harvested at 0, 2, 4, 6, 8 and 24 hours for immunofluorescence staining and FACS analysis.

HeLa cells were detached from culture flasks with  
25 trypsin-EDTA and washed once with D-PBS containing 5mM of EDTA. Cells were then fixed in 70% ethanol for 1 to 24 hours at 4°C followed by propidium iodine (PI, 50µg/ml) staining for 1 hour at room temperature. Cell counts (Y axis) and PI content (X axis) were determined  
30 by FACS analysis (Becton Dickinson and Co., San Jose, CA).

0390045-070001

**Example 9****Expression of GST-RNase III domain Fusion protein**

5 A cDNA fragment encoding the human RNase III-like domain (C-terminal-most 466 amino acids) was amplified by PCR and introduced into a BamH I site upstream and Not I site downstream. This fragment was further subcloned into the sites of the expression vector pGEX-4T-1 (Pharmacia Biotech, Piscataway, NJ) to produce the RNase III fusion protein with Glutathione S-transferase (GST) at its N-terminus. The identity of the construct was proven by DNA sequencing. The GST-RNase III fusion protein was expressed in *E.coli* strain BL21 and purified using glutathione agarose (Pharmacia Biotech, Piscataway, NJ) under native conditions with B-PER bacterial protein extraction reagent (Pierce, Rockford, IL). Control GST protein was also prepared in parallel from the pGEX-4T-1 plasmid. The purified products were identified by Coomassie staining after 12% SDS-polyacrylamide gel electrophoresis and Western blot analyses with anti-RNase III peptide antibody (see examples above).

**Example 10****In Vitro Cleavage of dsRNA**

25 The dsRNA substrate was generated by hybridization of two complementary strands of RNA produced with T7 and T3 polymerase transcription of the polylinker region of the pBluscript II KS(-) plasmid (Stratagen, San Diego, CA). The plasmid was digested with either Sst I or Kpn I and further purified with phenol/chloroform extraction and ethanol precipitation. The Sst I or Kpn I-digested plasmids were then

transcribed using T7 or T3 RNA polymerase respectively (Stratagene, San Diego, CA) with or without  $^{32}\text{P}$ - $\alpha\text{UTP}$ . The resulting transcribed RNAs (about 100 nt) were purified by electrophoresis on 6% denaturing polyacrylamide gel. The  $^{32}\text{P}$  radiolabeled T7 transcript and unlabeled T3 transcript fragments were mixed and heated for 5 min at  $90^\circ\text{C}$  in a buffer containing 20 mM KCl, 50 mM Tris-HCl (pH 7.5), 0.1 mM EDTA. MgCl, BSA and RNase inhibitor were added to the mixture after heating (final concentrations were 10 mM, 100 ng/ml and 10 unit/ml respectively). The mixture was incubated at  $37^\circ\text{C}$  for 2 hr and the duplex RNA was purified on 6% non-denaturing gels. The  $^{32}\text{P}$ -labelled T7 transcript was also used as the ssRNA control substrate. To evaluate cleavage, 0.4  $\mu\text{g}$  of GST protein or GST-RNase III (approximately 5-10 pmole of purified GST-RNase III) fusion protein was incubated with labeled dsRNA (250,000 cpm) (approximately 5-10 fmole) and ssRNA (250,000 cpm) at  $37^\circ\text{C}$  in a buffer containing 20 mM KCl, 50 mM Tris-HCl (pH 7.5), 5 mM MgCl, 50 mM NaCl, 0.1 mM DTT, 0.1 mg/ml yeast tRNA and 10 unit/ml RNase inhibitor in the total volume of 60  $\mu\text{l}$ . The digested samples were quenched at specific times and analyzed using non-denaturing polyacrylamide gel electrophoresis and PhosphorImager analysis.